Dear EURETINA Members, A very warm welcome to the June 23rd, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 23rd, 2025 “EURETINA-Brief”© Issue No. 319
Researchers based in Moorfields Eye Hospital, NHS Foundation Trust, London, have presented the first genome-wide association study (GWAS) results involving reticular pseudodrusen (RPD). The study’s… Read More »First genome-wide association study (GWAS) on reticular pseudodrusen (RPD) provides a clear relationship between RPD and the ARMS2-HTRA1 locus.
An independent study, funded by the Swedish government, has reported that intravitreal injections of anti-VEGF treatments were associated with a 2.9% risk for stroke among… Read More »Swedish clinical study reports a 3% increased risk of stroke within 90 days of anti-VEGF treatments.
VeonGen Therapeutics GmbH, based in Munich, Germany, have announced the progression of two proprietary gene therapies to the clinic based on a novel gene therapy… Read More »VeonGen Therapeutics GmbH announce re-branding of the company (previously ViGeneron) and the progression of treatments for Stargardt’s disease and retinitis pigmentosa.
Dear EURETINA Members, A very warm welcome to the June 9th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 9th, 2025 “EURETINA-Brief”© Issue No. 318
Mr. Robert F. Kennedy Jr., United States Secretary of Health & Human Services (HHS), has stated that government scientists who publish in a number of… Read More »Research published in The Lancet, the New England Journal of Medicine, and the Journal of the American Medical Association may be barred by the US Department of Health & Human Services (HHS).
A Phase 3 randomised clinical trial has recruited of >400 patients in a seven-month period, driven by clinical and patient interest, according to the trial’s… Read More »Phase 3 trial of vorolanib intravitreal insert, using a tyrosine kinase inhibitor (TKI), will be evaluating for wet age-related macular degeneration (wet AMD).
An innovative biomedical company, deepeye Medical GmbH, based in Munich Germany, has received a regulatory CE mark (Class IIa) service for a novel AI tool… Read More »First predictive AI tool for retinal therapy planning receives a European CE-mark (Class IIa) by deepeye Medical (Munich).
Dear EURETINA Members, A very warm welcome to the May 26th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »May 26th, 2025 “EURETINA-Brief”© Issue No. 317
Researchers at the University College London, Institute of Ophthalmology, and Moorfields Eye Hospital, NHS Foundation Trust, UK, reported a study indicating that large disparities of… Read More »A research survey is the first to evaluate patient perspectives and considerations regarding the application of AI in the diagnosis of IRDs.
